A Cancer-free India

Vopec Pharmaceutical's primary mission is finding a cure for diseases impacting humanity. Although an ambitious vision, Vopec’s technology originates from an eclectic hybrid model of combining both the wisdom traditions of India with the biotech of the Western world.

The success of the hybrid model led Vopec to a Phase 1 study on metastatic cancers and sister concern Agastiya Biotech’s FDA Orphan Drug Designation for 3 metastatic cancers. Dr Pillai claims of the success of this innovative therapeutic model is in the small molecules ability to work at quantum levels as proved by pharmacokinetics and pharmacodynamics studies.

A Cancer-Free India
A Cancer-Free India

The US FDA has awarded Orphan Drug Designations for Glioblastoma, Pancreatic and Acute Myeloid Leukemia indications for AB001. These rare cancers are generally considered a death sentence. AB001 may prove to be the answer.

Agastiya Biotech and Vopec Pharmaceuticals create toxicity-free / negligibly toxic small molecules, an unmet need of the pharmaceutical industry. Toxicity is the biggest challenge in drug discovery. It not only delays the drug approval process but results in less efficacy and drives up drug costs.